Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia

What this Trial Is About

Researchers are investigating the effectiveness of a new self-administered digital app called DREAMLAND to improve long-term quality of life and psychological health for patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy. AML patients face sudden, severe illness requiring urgent hospitalization and intensive treatment, which often leads to significant physical symptoms and psychological distress due to isolation and loss of independence during treatment. This study aims to compare DREAMLAND with another app, VITAL WELLNESS, to better support patients during this difficult period. DREAMLAND is a mobile psychological tool with four modules focused on psychotherapy, education, coping skills, and self-care, designed for use during a 4-6 week hospital stay for chemotherapy. Patients will be randomly assigned to either use DREAMLAND or VITAL WELLNESS, which offers physical health education on wellness, nutrition, exercise, and cancer prevention. Both apps are self-administered, with patients encouraged to complete one module each week during hospitalization. Participants will be closely monitored with patient-reported measures including quality of life, anxiety, depression, symptom burden, coping, and self-efficacy at various points up to 180 days after starting treatment. The study also examines the impact of the apps on psychological distress and symptom management. Enrollment is open to adults aged 18 to 120 with AML starting intensive chemotherapy, and outcomes will help determine the broader usefulness of DREAMLAND across different care settings.

Novel Digital Application for Patients With Acute Leukemia